Three COVID-19 treatments for adults should be made available via routine commissioning on the National Health Service in England outside pandemic situations, according to final draft guidance issued by the health technology assessment institute, NICE.
The products are Pfizer Inc.’s Paxlovid (nirmatrelvir plus ritonavir), GSK plc’s Xevudy (sotrovimab) and Roche Holding AG’s RoActemra (tocilizumab)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?